Press Releases

Highlights include the company’s significant progress in 2022 to create a more sustainable R&D model and advance potential new medicines to patients Salt Lake City , March 28, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology

SALT LAKE CITY , March 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Morgan Stanley Technology, Media & Telecom

Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readouts Delivered against core elements of our Roche-Genentech collaboration (neuroscience and an indication in gastrointestinal oncology) and Bayer collaboration

Salt Lake City, Utah , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rare Disease advocacy organizations and biotech and healthcare industry leaders will partner to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease. On Rare Disease Day, Feb.

SALT LAKE CITY , Feb. 1, 2023 /PRNewswire/ --  Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:     SVB Securities Global Biopharma Conference — February 14

For the first time ever, a demonstration version of one of Recursion's Compound Intelligence tools to explore maps of biology and chemistry is open for anyone to use RxRx3, the underlying dataset released alongside MolRec™, spans almost the entire human genome and is 76 times larger than all

SALT LAKE CITY , Dec. 20, 2022 /PRNewswire/ --  Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:     41st Annual J.P.

Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatment of  Clostridium difficile  colitis Nominated a new clinical program in  AXIN1 / APC  mutant cancers with an initial focus on

SALT LAKE CITY, Nov. 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: Credit Suisse 31st Annual Healthcare Conference — 

SALT LAKE CITY , Oct. 25, 2022 / PRNewswire / -- Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million